Advanced search
Publication Cover
Artificial Cells, Nanomedicine, and Biotechnology
An International Journal
Volume 45, 2017 - Issue 2
Submit an article Journal homepage
3,030
Views
43
CrossRef citations to date
0
Altmetric
Original Articles

Enhanced brain targeting efficacy of Olanzapine through solid lipid nanoparticles

Jawahar NatarajanDepartment of Pharmaceutics, JSS College of Pharmacy, Udhagamandalam, JSS University, Mysore, India; Correspondence[email protected]
,
Mahendran BaskaranDepartment of Pharmaceutics, JSS College of Pharmacy, Udhagamandalam, JSS University, Mysore, India;
,
Lireni C. HumtsoeDepartment of Pharmaceutics, JSS College of Pharmacy, Udhagamandalam, JSS University, Mysore, India;
,
R. VadivelanDepartment of Pharmacology, JSS College of Pharmacy, Udhagamandalam, JSS University, Mysore, India
&
A. JustinDepartment of Pharmacology, JSS College of Pharmacy, Udhagamandalam, JSS University, Mysore, India
Pages 364-371 | Received 04 Oct 2015, Accepted 26 Feb 2016, Published online: 22 Mar 2016

Figures & data

Table 1. particle size, zeta potential, and entrapment efficiency.

Figure 1. Differential scanning calorimeter curves of OLZ and OLZ-SLN formulations. OLZ: Olanzapine; TP: glyceryl tripalmitate; GMS: glyceryl monostearate; SLNs: solid lipid nanoparticles.

Figure 1. Differential scanning calorimeter curves of OLZ and OLZ-SLN formulations. OLZ: Olanzapine; TP: glyceryl tripalmitate; GMS: glyceryl monostearate; SLNs: solid lipid nanoparticles.

Figure 2. SEM image of SLN.

Figure 2. SEM image of SLN.

Figure 3. Comparative in vitro release profile in phosphate buffer saline pH 7.4.

Figure 3. Comparative in vitro release profile in phosphate buffer saline pH 7.4.

Figure 4. Higuchi’s plot for TP-SLN.

Figure 4. Higuchi’s plot for TP-SLN.

Figure 5. Higuchi’s plot for GMS-SLN.

Figure 5. Higuchi’s plot for GMS-SLN.

Table 2. Regression value for various kinetic models.

Figure 6. Korsmeyer–Peppa’s plot for TP-SLN.

Figure 6. Korsmeyer–Peppa’s plot for TP-SLN.

Figure 7. Korsmeyer–Peppa’s plot for GMS-SLN.

Figure 7. Korsmeyer–Peppa’s plot for GMS-SLN.

Table 3. Pharmacokinetic parameters for OLZ in the plasma after i.v. administration.

Figure 8. Concentration–time curve of TP-SLN and OLZ-suspension.

Figure 8. Concentration–time curve of TP-SLN and OLZ-suspension.

Figure 9. The concentration–time curve of TP-SLN and OLZ-Suspension in the brain.

Figure 9. The concentration–time curve of TP-SLN and OLZ-Suspension in the brain.

Table 4. Pharmacokinetic parameters for formulation and pure drug in brain.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related Research Data

Fabrication of Niclosamide loaded solid lipid nanoparticles: in vitro characterization and comparative in vivo evaluation
Source: (:unav)
The Effect of Minor Doses of Olanzapine-Solid Lipid Nanoparticles on an Animal Model of Schizophrenia (Neurochemical and Behavioral Study) and the Side Effect
Source: Bentham Science Publishers Ltd.

Linking provided by 

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.